Clinical Trial Update: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of stereotactic radiation and abemaciclib for HR-positive, HER2-negative metastatic breast cancer with brain metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Brain Metastases, HR+ Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING